

Quarterly statement.

January – September 2026

Quarterly statement January - September

Financials 9M 2026

- Core revenue increased to € 1,251.8 million (9M 2025: € 1,157.7 million)
- Organic core revenue growth of 6.6% (9M 2025: 11.5%)
- Underlying core EBITDA at € 327.1 million (9M 2025: € 281.1 million)
- Underlying core EBITDA margin improved to 26.1% (9M 2025: 24.3%)
- Underlying net income increased to € 138.0 million (9M 2025: € 118.7 million)
- Free cash flow of € 151.1 million (9M 2025: € 172.8 million), € 21.7 million below prior year due to higher tax payments
- Guidance for financial year 2026 confirmed:
  Organic core revenue growth 6.0% - 8.0%
  Underlying core EBITDA margin of more than 27.0%

Significant developments

- Continued trend from the first half of 2026 with a significant margin improvement
- Product launches of a new myoelectric prosthetic hand (*michelangelo*), the 3D-printed custom liner *iconiq* and the *C-Brace Interim*, a mechatronic knee-ankle-foot orthotic for early rehabilitation at the OTWorld trade fair in Leipzig
- Acquisition of Blatchford's patient care business in Norway in May 2026
- Continued carve-out process after signing of a sales agreement for the Human Mobility wheelchair business in June 2026
- Strategic expansion of the product portfolio in Functional Electrical Stimulation (FES) for neuro-orthotics with the acquisition of the Spanish entity Fesia Technology, S.L. in July[1]

[1] Not listed: investment in the field of human-machine interfaces with Blue Arbor Technologies, Inc. in February 2026, expansion of the worldwide patient care network with the acquisition of the Italian patient care business Rehattiva Srl in July 2026

Key figures

	Q3		9M		Change
million €	**2026**	**2025**	**2026**	**2025**	**in %**
Revenue	453.8	417.2	1,307.9	1,217.8	7.4%
Revenue growth	8.8%	3.9%	7.4%	4.6%	2.8%p
Core revenue	**433.4**	**397.5**	**1,251.8**	**1,157.7**	8.1%
Organic core revenue growth	**6.4%**	**12.7%**	**6.6%**	**11.5%**	-4.9%p
Gross profit	249.4	221.7	697.9	645.4	8.1%
Gross margin	55.0%	53.1%	53.4%	53.0%	0.4%p
Underlying EBITDA	123.2	109.3	336.5	289.6	16.2%
Underlying EBITDA margin	27.2%	26.2%	25.7%	23.8%	1.9%p
Underlying core EBITDA	**120.1**	**105.8**	**327.1**	**281.1**	16.4%
Underlying core EBITDA margin	**27.7%**	**26.6%**	**26.1%**	**24.3%**	1.9%p
EBITDA	118.5	86.8	326.6	250.4	30.4%
EBITDA margin	26.1%	20.8%	25.0%	20.6%	4.4%p
Net income	47.8	26.4	115.1	54.3	111.9%
Net income margin	10.5%	6.3%	8.8%	4.5%	4.3%p
Underlying net income	**52.9**	**50.0**	**138.0**	**118.7**	16.3%
Underlying net income margin	**11.7%**	**12.0%**	**10.6%**	**9.7%**	0.8%p
Operating cash flow	100.3	108.0	218.3	242.8	-10.1%
Free cash flow	79.3	79.6	151.1	172.8	-12.6%
Leverage	2.3	2.8	2.3	2.8	-17.5%
Employees (average FTE)	9,552	9,336	9,455	9,256	2.1%
CapEx	-20.9	-28.3	-67.2	-70.0	-4.0%
Earnings per share	€ 0.75	€ 0.41	€ 1.79	€ 0.87	104.7%

Business development of the Group

Results of operations

Revenue

In the first nine months of 2026, Ottobock increased its revenue by 7.4% to € 1,307.9 million (9M 2025: € 1,217.8 million). Acquisitions contributed 1.7 percentage points to revenue growth. Particularly the acquisition of Blatchford Norway AS ("Blatchford Norway") in 2026 contributed to this development with revenue of € 16.7 million. The impact of currency effects amounted to € –2.1 million.

Core revenue amounted to € 1,251.8 million (9M 2025: € 1,157.7 million), corresponding to an organic core revenue growth of 6.6% against strong comparative period.

Revenue by segment

The focus of global activities was in the EMEA segment with a revenue share of 73.5% (9M 2025: 71.2%), followed by Americas with 19.7% (9M 2025: 21.9%) and APAC with 6.8% (9M 2025: 6.9%).

Revenue by segment

	9M		Change	Organic growth
million €	2026	2025	in %	in %
EMEA	961.4	867.3	10.9%	8.1%
Americas	257.6	266.4	-3.3%	-1.2%
APAC	88.9	84.1	5.8%	7.1%
Total revenue	**1,307.9**	**1,217.8**	**7.4%**	**6.0%**

Within EMEA, revenue increased by € 94.1 million or 10.9% to € 961.4 million in the reporting period. The overall positive development is primarily attributable to double-digit organic growth in the B2B business, where Russia and Ukraine continued to deliver a positive contribution to growth. This development was partially offset by softer performance in Western Europe, where more challenging reimbursement processes have lengthened the time required to translate underlying patient demand into revenue. The B2C business also showed continuous organic growth. In addition to organic growth, acquisitions in EMEA contributed € 21.0 million to the year-over-year development. In the first nine months of 2026, Russia contributed more than 11% to the Group's revenue.

Revenue in the Americas segment amounted to € 257.6 million in the first nine months of 2026, reflecting a decline of € 8.8 million or 3.3% compared to the same period in the previous year (9M 2025: € 266.4 million). Revenue growth was impacted by negative foreign exchange effects. While organic B2C growth was positive, organic B2B growth declined against a strong comparative period. As a result, the organic core growth in Americas was -0.8%.

Within APAC, the revenue increased by € 4.8 million or 5.8% to € 88.9 million in the reporting period. After a weaker second quarter, growth gained momentum in the third quarter. Overall, business normalized and both the B2B and B2C businesses recorded positive organic growth rates, while the non-core business showed negative organic growth.

Core revenue by segment

	9M		Change	Organic growth
million €	2026	2025	in %	in %
EMEA	924.4	828.4	11.6%	8.7%
Americas	243.3	250.9	-3.0%	-0.8%
APAC	84.1	78.4	7.2%	8.6%
Core revenue	**1,251.8**	**1,157.7**	**8.1%**	**6.6%**

Revenue by product category

Products & components (B2B) accounted for 54.2% of revenue in the first nine months of 2026 (9M 2025: 53.4%), while patient care (B2C) contributed 41.5% (9M 2025: 41.7%). The share of the non-core business amounted to 4.3% (9M 2025: 4.9%).

Revenue by product category

	9M		Change	Organic growth
million €	**2026**	**2025**	**in %**	**in %**
Products & components (B2B)	709.3	650.1	9.1%	9.1%
Patient care (B2C)	542.6	507.7	6.9%	3.3%
Core revenue	**1,251.8**	**1,157.7**	**8.1%**	**6.6%**
Non-core revenue	56.1	60.0	-6.5%	
Total revenue	**1,307.9**	**1,217.8**	**7.4%**	**6.0%**

Revenue in the B2B business amounted to € 709.3 million in the reporting period. This reflects an increase of € 59.2 million or 9.1% (9M 2025: € 650.1 million), corresponding to an organic revenue growth of 9.1%. Revenue growth was mainly attributable to continued positive momentum in prosthetics and neuro-orthotics, particularly in high-tech components, as well as positive contributions from innovations such as the myoelectric *michelangelo* hand.

B2C revenue increased by 6.9% or € 34.9 million to € 542.6 million in the reporting period (9M 2025: € 507.7 million). This increase was driven by continuous organic revenue growth across all segments and acquisitions.

Non-core revenue decreased by 6.5% to € 56.1 million in the reporting period (9M 2025: € 60.0 million), mainly due to lower human mobility revenue.

Organic growth rates by segment and product category

9M 2026	B2B	B2C	Core	Total
EMEA	14.4%	3.1%	8.7%	8.1%
Americas	-2.3%	3.6%	-0.8%	-1.2%
APAC	9.3%	6.2%	8.6%	7.1%
Organic growth	**9.1%**	**3.3%**	**6.6%**	**6.0%**

Gross profit

Cost of sales increased to € 610.0 million in the first nine months of 2026, up 6.6% compared to the prior-year period (9M 2025: € 572.4 million). In combination with € 90.2 million revenue growth, this results in an increase in gross profit by € 52.5 million to € 697.9 million (9M 2025: € 645.4 million). A positive development in material costs and a tariff refund of € 1.2 million in the US lead to an increase of the gross margin from 53.0% to 53.4%.

Operating expenses

Despite higher marketing costs related to the Paralympic Winter Games and the OTWorld in 2026 as well as higher extraordinary expenses in connection with a software implementation, selling expenses increased only by € 3.0 million to € 259.6 million in the first nine months of 2026 (9M 2025: € 256.6 million). The ratio of selling expenses to revenue decreased from 21.1% to 19.9%,.

R&D expenses increased by € 5.8 million to € 60.3 million in the reporting period (9M 2025: € 54.4 million). The increase is mainly attributable to regular cost increases, a lower capitalization rate of 56.9% (9M 2025: 58.5%), and higher impairments. The ratio of R&D expenses to revenue was with 4.6% slightly above prior year (9M 2025: 4.5%).

Administrative expenses decreased by € 19.3 million to € 164.5 million in the first nine months of 2026 (9M 2025: € 183.9 million). The prior-year period was impacted by higher extraordinary items, such as the revaluation of the Management Participation Program (“MPP”), IPO costs and transaction costs related to the intended sale of the human mobility business.

The net amount of other operating income and expenses amounted to € -1.2 million, representing an improvement of € 31.3 million compared to the prior-year period. This was primarily due to the decrease of negative foreign exchange effects as well as non-recurring impairments incurred in the prior year in connection with the intended sale of the human mobility business.

As a result of the developments and effects described above, the operating profit (EBIT) improved by 80.0% to € 212.3 million (9M 2025: € 117.9 million), which corresponds to an EBIT margin of 16.2% (9M 2025: 9.7%).

Underlying EBITDA

In the first nine months of 2026, the underlying EBITDA reached € 336.5 million, representing an increase of € 46.9 million or 16.2% compared to the prior-year period (9M 2025: € 289.6 million). This development is attributable to a robust organic revenue growth, a favorable product mix driven by stronger growth in the B2B business, as well as scaling effects and disciplined cost management in administrative and operations functions.

Underlying EBITDA by segment

	9M		Change
million €	**2026**	**2025**	**in %**
EMEA	254.1	208.2	22.0%
Americas	60.5	60.3	0.3%
APAC	21.9	21.0	4.2%
Underlying EBITDA	**336.5**	**289.6**	**16.2%**

Underlying core EBITDA amounted to € 327.1 million, representing an increase of € 46.1 million or 16.4% compared to the prior-year period (9M 2025: € 281.1 million). The underlying core EBITDA margin improved by 1.9 percentage points from 24.3% in 2025 to 26.1% in 2026. The underlying non-core EBITDA amounted to € 9.3 million, corresponding to an increase by € 0.8 million in the reporting period (9M 2025: € 8.5 million).

Underlying core EBITDA by segment

	9M		Change
million €	**2026**	**2025**	**in %**
EMEA	246.8	201.9	22.2%
Americas	59.1	59.0	0.1%
APAC	21.3	20.1	5.6%
Underlying core EBITDA	**327.1**	**281.1**	**16.4%**

Underlying core EBITDA margin by segment

	9M		Change
in % of core revenue	**2026**	**2025**	**in %p**
EMEA	26.7%	24.4%	2.3%p
Americas	24.3%	23.5%	0.8%p
APAC	25.3%	25.7%	-0.4%p
Underlying core EBITDA margin	**26.1%**	**24.3%**	**1.9%p**

Reconciliation of EBT to underlying core EBITDA

	9M		Change
million €	2026	2025	in %
EBT	**166.6**	**86.1**	93.5%
Financial result	45.6	31.8	43.4%
EBIT	**212.3**	**117.9**	80.0%
Depreciation	109.2	101.3	7.8%
Impairment	5.1	31.2	-83.6%
EBITDA	**326.6**	**250.4**	30.4%
Restructuring and major corporate projects	7.7	35.9	-78.7%
Mergers, acquisitions and divestments	2.2	3.3	-32.0%
Extraordinary items	9.9	39.2	-74.7%
Underlying EBITDA	**336.5**	**289.6**	16.2%
Underlying non-core EBITDA	9.3	8.5	9.1%
Underlying core EBITDA	**327.1**	**281.1**	16.4%

Underlying net income

The underlying net income reached € 138.0 million in the first nine months of 2026, up from € 118.7 million in the prior year reporting period. This corresponds to an underlying net income margin of 10.6% (9M 2025: 9.7%). The increase in underlying net income is primarily driven by improved operating results. Depreciation without impairments increased in line with the normal course of business. The interest result improved by € 2.7 million compared to 2025 due to lower average bank borrowings. Current income tax expense increased by € 22.3 million driven by the higher EBT in the reporting period.

Reconciliation of underlying EBITDA to (underlying) net income

	9M		Change
million €	2026	2025	in %
Underlying EBITDA	**336.5**	**289.6**	**16.2%**
Depreciation (excl. impairments)	-109.2	-101.3	7.8%
Interest result	-37.4	-40.1	-6.8%
Current income tax expense	-51.9	-29.6	75.4%
Ordinary deduction items	-198.4	-170.9	16.1%
Underlying net income	**138.0**	**118.7**	**16.3%**
Restructuring and major corporate projects	-7.7	-35.9	-78.7%
Mergers, acquisitions and divestments	-2.2	-3.3	-32.0%
Extraordinary items	-9.9	-39.2	-74.7%
Impairments	-5.1	-31.2	-83.6%
Other financial result	-8.3	8.3	-199.9%
Deferred tax expense	0.4	-2.2	-116.1%
Other deduction items	-13.0	-25.2	-48.2%
Net income	**115.1**	**54.3**	**111.9%**

Restructuring and major corporate projects mainly included one-time implementation costs for SAP S/4HANA, restructuring-related severance payments and costs associated with the establishment of the global shared service center in Bulgaria. The previous year was impacted by the revaluation of the MPP as well as costs in connection with the IPO. Costs for mergers, acquisitions and divestments in the first nine months of 2026 primarily included expenses related to the planned divestment of the human mobility business.

Impairments in the first nine months of 2026 were, besides R&D projects, also related to the intended divestment of the human mobility business.

Other financial result comprised income from the revaluation of call options amounting to € 4.6 million. The income could not compensate the negative effects from fair value changes in foreign exchange derivatives of € -8.2 million and negative effects from exchange differences in intercompany loans of € -4.1 million, leading to an other financial result of € -8.3 million (9M 2025: € 8.3 million).

As a result, net income increased by € 60.8 million to € 115.1 million in the first nine months of 2026, mainly due to a higher underlying EBITDA and lower extraordinary items and impairments.

Financial position

Free cash flow amounted to € 151.1 million in the first nine months of 2026, representing a decrease of € 21.7 million compared to the prior year (9M 2025: € 172.8 million). EBITDA, which has a significant impact on free cash flow, increased by € 76.1 million to € 326.6 million. This development was partly attributable to non-cash expenses recognized in the prior year, including expenses arising from the revaluation of the MPP and provisions for employee bonuses, which were paid out in the first half of 2026. In addition, income tax paid increased by € 33.9 million to € 67.2 million.

Guidance 2026

Based on the good business performance in the first nine months of 2026, Ottobock confirms its full-year guidance for the Group. Organic core revenue growth is expected in a range between 6%-8%. Underlying core EBITDA margin is expected to be more than 27.0%.

Consolidated statement of profit or loss

	Q3		9M	
million €	**2026**	**2025**	**2026**	**2025**
Revenue	**453.8**	**417.2**	**1,307.9**	**1,217.8**
Cost of sales	-204.4	-195.5	-610.0	-572.4
Gross profit	**249.4**	**221.7**	**697.9**	**645.4**
Other operating income	8.1	9.3	23.9	20.7
Selling expenses	-87.3	-87.7	-259.6	-256.6
Research and development expenses	-19.8	-17.0	-60.3	-54.4
Administrative expenses	-58.0	-66.8	-164.5	-183.9
Other operating expenses	-12.0	-7.7	-25.1	-53.3
Operating profit (EBIT)	**80.5**	**51.7**	**212.3**	**117.9**
Interest income	0.9	0.6	2.6	2.8
Interest expenses	-13.9	-13.6	-40.0	-42.9
Other financial result	-0.1	1.6	-8.3	8.3
Financial result	**-13.0**	**-11.4**	**-45.6**	**-31.8**
Profit before tax (EBT)	**67.4**	**40.3**	**166.6**	**86.1**
Income taxes	-19.6	-13.9	-51.6	-31.8
Profit for the period	**47.8**	**26.4**	**115.1**	**54.3**
of which attributable to shareholders of Ottobock SE & Co. KGaA	48.1	26.5	115.9	55.9
of which attributable to non-controlling interests	-0.3	-0.1	-0.8	-1.6
Earnings per share (basic and diluted)	**€ 0.75**	**€ 0.41**	**€ 1.79**	**€ 0.87**

Consolidated statement of other comprehensive income

	Q3		9M	
million €	**2026**	**2025**	**2026**	**2025**
Profit for the period	**47.8**	**26.4**	**115.1**	**54.3**
Cash flow hedges	2.3	0.8	2.9	2.9
Exchange differences on translation of foreign operations	-35.4	-4.9	-24.2	-29.6
Items that may be reclassified to profit or loss	**-33.1**	**-4.1**	**-21.2**	**-26.7**
Remeasurement of net defined benefit obligations	1.1	0.0	2.0	0.8
Equity instruments designated at fair value through OCI	1.0	3.2	-11.7	-0.3
Items not reclassified to profit or loss	**2.1**	**3.2**	**-9.7**	**0.5**
Other comprehensive income (loss) after taxes	**-31.0**	**-0.8**	**-31.0**	**-26.2**
Total comprehensive income	**16.8**	**25.5**	**84.1**	**28.1**
of which attributable to shareholders of Ottobock SE & Co. KGaA	17.0	25.7	85.0	29.6
of which attributable to non-controlling interests	-0.2	-0.2	-0.8	-1.5

Consolidated statement of financial position

million €	30 September 2026	31 December 2025
Property, plant and equipment	234.1	236.9
Goodwill	577.9	509.8
Intangible assets	393.0	343.4
Right-of-use assets	209.4	195.4
Equity-accounted investees	14.6	8.1
Other financial assets	43.1	46.0
Other assets	2.6	3.7
Deferred tax assets	78.2	73.9
Non-current assets	**1,552.9**	**1,417.3**
Inventories	247.9	215.6
Trade receivables	237.7	211.0
Other financial assets	11.9	20.7
Cash and cash equivalents	99.3	90.4
Other assets	70.4	54.4
Income tax assets	32.7	22.2
Assets held for sale	20.6	18.1
Current assets	**720.5**	**632.3**
Total assets	**2,273.4**	**2,049.6**

million €	30 September 2026	31 December 2025
Subscribed capital	64.0	64.0
Capital reserve	153.8	153.8
Retained earnings	276.5	223.4
Other components of equity	-41.8	-51.1
Equity attributable to shareholders of Ottobock SE & Co. KGaA	**452.5**	**390.1**
Non-controlling interests	5.3	7.4
Total equity	**457.8**	**397.5**
Liabilities to credit institutions	888.1	651.6
Lease liabilities	172.9	159.7
Other financial liabilities	11.2	13.4
Other provisions	11.8	10.6
Contract liabilities	46.1	42.2
Employee benefit liabilities	22.6	24.3
Other liabilities	13.6	8.4
Deferred tax liabilities	88.2	74.4
Non-current liabilities	**1,254.5**	**984.7**
Liabilities to credit institutions	71.5	198.0
Lease liabilities	42.8	41.8
Trade payables	115.1	99.6
Contract liabilities	36.3	32.2
Other financial liabilities	28.8	31.6
Payables from reverse factoring	71.1	66.6
Income tax payable	31.4	37.1
Other provisions	36.8	33.3
Employee benefit liabilities	86.2	90.8
Other liabilities	30.1	24.8
Liabilities directly associated with the assets held for sale	11.1	11.8
Current liabilities	**561.1**	**667.5**
Total equity and liabilities	**2,273.4**	**2,049.6**

Consolidated statement of cash flows

	Q3		9M	
million €	**2026**	**2025**	**2026**	**2025**
Profit before tax (EBT)	67.4	40.3	166.6	86.1
Financial result	13.0	11.4	45.6	31.8
Depreciation, amortization and impairment	38.1	35.1	114.3	132.5
Gain from disposals of non-current assets	-0.1	-0.1	-0.4	-0.6
Changes in liabilities from the Management Participation Program	-	12.1	-	17.5
Other non-cash expenses and income	-3.6	-0.1	1.7	-5.0
Change in operating assets and liabilities				
Inventories	-8.1	-2.4	-30.0	-25.4
Trade receivables	6.8	10.9	-13.1	15.5
Other assets	-6.9	-0.1	-20.0	-8.2
Other provisions	3.3	3.9	4.5	4.9
Trade payables	-1.0	4.1	8.4	-15.6
Other liabilities	13.4	22.5	7.8	42.6
Income tax paid	-21.9	-29.6	-67.2	-33.3
Cash flow from operating activities	**100.3**	**108.0**	**218.3**	**242.8**
Additions to property, plant and equipment and intangible assets	-22.5	-28.9	-69.8	-76.1
Disposals of property, plant and equipment and intangible assets	1.6	0.6	2.6	6.1
Free cash flow[1]	**79.3**	**79.6**	**151.1**	**172.8**
Acquisition of subsidiaries and other businesses	-0.5	-12.2	-112.0	-29.6
Earn-out payments and payments of deferred purchase prices	0.0	-8.0	-0.8	-10.5
Acquisition of investments	-	-	-6.7	-6.6
Acquisition of other financial assets	-	-	-	-1.6
Dividends received	-	0.3	-	0.3
Cash flows from investing activities	**-21.4**	**-48.3**	**-186.6**	**-118.1**

1 The Group defines free cash flow as cash flow from operating activities less payments for the acquisition of tangible and intangible assets, and adjusted for gains or losses from their disposal.

	Q3		9M	
million €	**2026**	**2025**	**2026**	**2025**
Proceeds from bank loans	-19.2	-24.6	250.8	-17.5
Repayment of bank loans	-24.4	-	-147.0	-
Repayment of lease liabilities	-11.6	-10.6	-33.9	-32.2
Dividends paid	-	-0.1	-62.1	-15.1
Acquisition of non-controlling interests	-0.9	-0.9	-1.3	-0.9
Interest paid	-16.9	-12.8	-39.4	-41.0
Capital contributions by shareholders	-	-	8.4	-
Change in other financing activities	-0.7	2.0	1.7	7.1
Cash flows from financing activities	**-73.5**	**-47.0**	**-22.7**	**-99.5**
Change in cash and cash equivalents	**5.3**	**12.7**	**9.0**	**25.3**
Cash and cash equivalents at the beginning of the period	93.6	87.8	90.4	76.7
Effect of foreign exchange rate changes on cash and cash equivalents	0.2	-1.2	-0.1	-2.0
Reclassifications relating to assets held for sale	0.1	0.1	0.0	-0.5
Cash and cash equivalents at the end of the period	**99.3**	**99.4**	**99.3**	**99.4**

Financial calendar

16 February 2027
Preliminary Financial Results 2026

11 March 2027
Annual Report 2026

29 April 2027
Annual General Meeting

5 May 2027
Quarterly Statement January - March 2027

12 August 2027
Half-year Financial Report January - June 2027

4 November 2027
Quarterly Statement January - September 2027

Imprint

Investor contact:
Jens-Philipp Briemle
Vice President Investor Relations
Mobile: +49 151 59167524
E-Mail: investors@ottobock.de

Media contact:
Merle Florstedt
Head of Corporate Communications
Mobile: +49 151 44161625
E-Mail: merle.florstedt@ottobock.de

Legal note

This financial report includes statements concerning the future performance of Ottobock. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Ottobock undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this financial report.

Other information

The present document is a quarterly statement pursuant to Section 53 of the Exchange Rules for the Frankfurter Wertpapierbörse (BörsO FWB). It was drawn up according to International Financial Reporting Standards (IFRS) as applicable in the EU, but does not constitute an interim financial report as defined by IAS 34 "Interim Financial Reporting" or a financial statement as defined by IAS 1 "Presentation of Financial Statements". The accounting policies essentially correspond to those applied in the consolidated financial statement as at 31 December 2025.

The key figures in the report are rounded in accordance with standard commercial practice. In individual cases, rounding may result in values in this report not adding up precisely to the amount stated, with corresponding percentages not tallying.

This Quarterly Statement was published on 12 November 2026. It is available in German and English. In the event of any discrepancies between the two versions, the German version shall take precedence.



Published by

Ottobock SE & Co. KGaA
Max-Näder-Str. 15
37115 Duderstadt
Germany
www.ottobock.com